Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Pancreatic cancer

Matrix metalloproteinase 2 (MMP2); MMP9

In vitro and mouse studies identified the endohedral metallofullerenol Gd@C82(OH)22 as an MMP inhibitor that could help treat pancreatic cancer. In mice with human pancreatic cancer xenografts, the nanoparticle suppressed tumor growth by decreasing angiogenesis and blood vessel size and density compared with saline control. In tumor sections, Gd@C82(OH)22 decreased MMP2 and MMP9 mRNA levels compared with saline. Next steps include mass production of the nanoparticle and a clinical trial.

SciBX 5(37); doi:10.1038/scibx.2012.980
Published online Sept. 20, 2012

Findings patented; additional patents to be filed for better compound designs; will be available for licensing

Kang, S.-g. et al. Proc. Natl. Acad. Sci. USA; published online Sept. 4, 2012;
doi:10.1073/pnas.1204600109
Contact: Ruhong Zhou, IBM
T.J. Watson Research Center,
Yorktown Heights, N.Y.
e-mail:
ruhongz@us.ibm.com
Contact: Yuliang Zhao, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing, China
e-mail:
zhaoyuliang@ihep.ac.cn
Contact: Chunying Chen,
same affiliation as above
e-mail:
chenchy@nanoctr.cn